Abstract
Leukemic stem cells (LSC) in acute myeloid leukemia (AML), defined by CD34 and CD38 antigens also express CD33 similar to normal hematopoietic stem cells. Residual LSC are believed to be responsible for relapse in AML after chemotherapy. Leukemic progenitor cell compartments were defined by CD34 and CD38 expression by flow cytometry in 61 new cases of AML. In each of four compartments thus defined, CD34+CD38−, CD34+CD38+, CD34−CD38− and CD34−CD38+, the pattern and intensity of expression of CD33 were studied in comparison to similar progenitor cell compartments in normal bone marrow and peripheral blood stem cell harvests. Post induction bone marrow samples from 10/61 cases were studied for aberrant CD33 expression. The intensity and pattern of expression of CD33 in AML progenitor cells were significantly different compared to normal progenitor cells. In two cases who were in morphological remission post induction, aberrant CD33 expressing progenitor cells were detectable at a frequency of 1.6 and 0.5 % respectively in the bone marrow. Aberrant CD33 expression in bone marrow LSC identified as CD34+CD38− cells in the CD45 dim/low side scatter region on flow cytometry may be useful as minimal residual disease marker after AML therapy. The method involves the use of a limited number of reagents and can be applied to all cases of AML.
This is a preview of subscription content, log in via an institution to check access.
References
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 7:730–737
Sutherland HJ, Blair A, Zapf RW (1996) Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 87:4754–4761
Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106(13):4086–4092
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al (2003) International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24):4642–4649
van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AWM et al (2007) Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21:1700–1707
Terwijn M, Kelder A, Rutten AP, Snel AN, Scholten W, Zweegman S et al (2009) LSC frequency in CR in CD34+ AML detected by aberrant marker expression and light scatter properties was shown to be superior in predicting prognosis compared to total blast MRD. Blood 114(22):399a
Gerber JM, Smith BD, Ngwang B, Vala MS, Morsberger L, Galkin S et al (2012) A clinically relevant population of leukemic CD34+CD38− cells in acute myeloid leukemia. Blood 119(15):3571–3577
Acknowledgments
We thank Dr. Purnima Sharma for help with statistical analysis and Dr. Hema Arora for technical help.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dutta, S., Saxena, R. The Expression Pattern of CD33 Antigen Can Differentiate Leukemic from Normal Progenitor Cells in Acute Myeloid Leukemia. Indian J Hematol Blood Transfus 30, 130–134 (2014). https://doi.org/10.1007/s12288-013-0317-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-013-0317-5